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2.2 ESSENTIAL TOOLS—DRUGS AND CLINICAL DRUG TRIALS
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Summary of Prioritized Research Needs
1) Create a framework for monitoring for potential develop-
ment of drug resistance, including
a) defining criteria for the phenotype of reduced respon-
siveness and resistance,
b) establishing a repository of mf and/or adult worms to
provide base-line data on the occurrence of drug-
resistant genotypes,
c) initiating a surveillance system for diminished respon-
siveness to anti-filarial drugs,
2) Initiate clinical trials of available anti-filarial drugs to
a) enhance mf reduction (through alternative dosages,
frequency regimens, etc.),
b) enhance adulticidal effectiveness,
c) define ways to minimize patient treatment reactions at
a population level,
d) define a standard treatment for individuals with LF,
3) Ensure the safety of coordinated administration of drugs
in linked public health programs (e.g., albendazole, iver-
mectin, azithromycin, praziquantel, etc.) or in other medi-
cal settings (e.g., used with human immunodeficiency vi-
rus/acquired immunodeficiency syndrome [HIV/AIDS] or
tuberculosis [TB] multidrug therapy regimens),
4) Establish a framework for seeking a macrofilaricide,
5) Pursue discovery of an anti-Wolbachia agent suitable for
MDAs and/or individual treatment,
6) Develop broadly applicable implementation strategies for
use of DEC-fortified salt (with or without concurrent al-
bendazole administration),
7) Evaluate use of moxidectin for LF.
2.2.1 Overview
Regimens currently in use.
A series of advances during the past decade transformed
LF from a neglected disease of poor countries into a disease
now recognized as potentially eradicable. Principal among the
reasons for these advances were the identification of ivermec-
tin and albendazole as new, effective anti-filarial agents and
the discovery of new virtues for an old anti-filarial drug, DEC
(i.e., its single-dose efficacy and macrofilaricidal action).
These discoveries were essential for the subsequent creation
of the Global Program to Eliminate LF,1 whose very basis is
the large-scale use of DEC, ivermectin (Mectizan; Merck
and Co., Inc., Rahway, NJ) and albendazole. Indeed, in many
endemic countries literally millions of tablets of these drugs
are distributed over a few short days each year (often on a
single day), making GPELF the largest chemotherapy pro-
gram ever undertaken.2
Currently it is just these three drugs that are available for
use in single-dose, annual MDA programs. Albendazole is
co-administered with ivermectin in areas of Africa and Ye-
men where LF and onchocerciasis are co-endemic. For all
other LF-endemic regions, albendazole is co-administered
with DEC. At the recommended dose levels, none of the
drugs is completely macrofilaricidal, although all appear to
inflict some lasting damage to adult worms. Both DEC and
ivermectin kill mf efficiently; albendazole, on the other hand,
has no direct effect on mf, but rather appears to suppress
embryogenesis in the adult female worm. An alternative
treatment strategy involving the use of DEC as a fortificant in
table/cooking salt for a period of 1−2 years is currently used
in just one country, but was a mainstay of the earlier, success-
ful LF elimination program in China.
Modes of action of available drugs.
The mechanisms by which ivermectin and albendazole
achieve parasite destruction have been well studied in other,
non-filarial organisms. Briefly, ivermectin binds selectively
and with high affinity to glutamate-gated chloride ion chan-
nels in invertebrate nerve and muscle cells. The molecule
increases permeability of the cell membrane to chloride ions,
resulting in hyperpolarization of nerve or muscle cells, caus-
ing parasite paralysis and death. The drug is also observed to
affect other ligand-gated chloride channels, particularly those
gated by gamma-aminobutyric acid.3 However, it is still not
certain why ivermectin shows activity only against mf, and not
adult worms.
The primary target for albendazole is tubulin, and the drug
is observed to have a higher affinity for parasite tubulin than
for that of the host.4 By blocking tubulin polymerization and
microtubule formation, the drug inhibits mitosis, and there-
fore embryonation and egg hatching. It is very likely that
albendazole exerts an effect on adult filariae in this manner.
In contrast, the understanding of how DEC achieves a le-
thal effect on either mf or adult worms is very poorly devel-
oped. There is some evidence that the drug may require co-
operation with a functional host immune system to be opti-
mally effective.5,6
How these drugs act in combination on different lifecycle
stages is not at all understood, or even well studied.
Resistance mechanisms.
All three of these anti-filarial drugs have been used exten-
sively in humans, and to date there has been no unequivocal
identification of resistance in LF to any of the drugs. While
this is clearly most encouraging, it is also not entirely surpris-
ing since currently there is no phenotypic definition of such
drug resistance and no comprehensive system for monitoring
and evaluating the phenomenon in humans.
The mechanisms by which resistance to albendazole is con-
ferred are well understood in nematode parasites of other
animals, and PCR-based methods for detection and analysis
of the expression of the beta-tubulin genes TUB1 and TUB2
are available. Resistance to albendazole appears to be asso-
ciated with a loss of high affinity receptors, resulting from
neucleotide changes, predominantly in the TUB1 gene.7,8** Other contributors in this working group are listed in Annex 2.
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Mechanisms controlling parasite sensitivity to ivermectin
appear to be considerably more complex. Studies on the nem-
atode Caenorhabditis elegans show that simultaneous muta-
tion of three genes (avr-14, avr-15, and glc-1) that encode
glutamate-gated chloride channel (GluCl) -type subunits
confers a high-level resistance to the drug.9,10
A decrease in sensitivity of filariae to DEC has been sug-
gested, particularly where the drug has been used for many
years. However, whether these observations reflect a geneti-
cally conferred resistance, deficiencies at a programmatic
level, or some other cause is as yet not certain.10,11 These
uncertainties are currently compounded by a lack of suitable
targets to facilitate the evaluation of DEC resistance in hu-
mans.
Safety of one- and two-drug regimens.
The safety of each of the three individual drugs used in the
GPELF has been well established. Diethylcarbamazine, in
use for nearly half a century, has proven to be extremely safe
and effective both in the clinic and the field without supervi-
sion; hundreds of millions of doses of ivermectin have been
safely distributed since the drug was introduced for the treat-
ment of onchocerciasis; and albendazole has been widely used
for several decades, again in hundreds of millions of people,
with a remarkable safety record. When co-administration of
these drugs was initiated through GPELF, active surveillance
programs were undertaken in all countries where MDAs
were begun. These documented thoroughly the safety of the
combinations in the field.12−14 (Only in areas of Africa en-
demic for loiasis, where severe adverse reactions may occur
with the administration of ivermectin, are MDAs for LF
elimination now contra-indicated because of safety concerns
[see below].)
2.2.2 Research Needs: Drug Development
Macrofilaricide.
While DEC and albendazole clearly have macrofilaricidal
effects,15,16 there is still recognition of the potential value a
more potent macrofilaricide would bring to efforts to achieve
LF elimination, not only in rapidly diminishing microfilare-
mia but also in halting progression of the initial morbidity
associated with the infection and induced largely by the adult-
stage worms. Since drug development is a long and costly
exercise, with the pharmaceutical industry being generally re-
luctant to invest in ventures that have little or no direct fi-
nancial return, any meaningful advance in the development of
a macrofilaricide will likely be feasible only if an effective
partnership between development agencies, academia, the
pharmaceutical industry, and funding organizations can be
established. Therefore,
• despite the complexity of the challenge, a working group
should be established to explore the creation of an anti-
filarial (and particularly, macrofilaricidal) drug develop-
ment partnership, and
• this partnership should focus not only on novel drugs but
also take leads from currently active drug classes and from
active compounds identified in ‘traditional’ medicine.
Anti-Wolbachia drugs.
Over recent years, alternative approaches to classical che-
motherapy have emerged as the Wolbachia endosymbionts of
filariae have been recognized as potential drug targets.17 In-
deed, treatment with the antibiotic doxycycline for six weeks
depletes Wolbachia from W. bancrofti, yielding an almost
complete absence of microfilaremia one year later and sug-
gesting effective, long-term block of embryogenesis18 and/or
macrofilaricidal activity. Since treatment of filariasis with
such protracted regimens of antibiotics is not compatible with
the principles of mass chemotherapy, an important challenge
today is
• to identify or develop alternative antibiotics or regimens
effective against Wolbachia that could be used in MDA
programs and/or offer specific treatment to infected indi-
viduals.
Moxidectin.
Studies to evaluate moxidectin as an alternative to ivermec-
tin for the treatment of onchocerciasis have shown moxidec-
tin to be more effective than ivermectin in most animal mod-
els.19 The drug has potent effects on mf and results in long-
term sterilization of female adult worms, but there is no
evidence as yet showing that moxidectin is macrofilaricidal.
Moxidectin is currently being evaluated as a treatment for
onchocerciasis through a partnership involving WHO and the
owner (American Home Products [Wyeth]). If the evaluation
of moxidectin for human onchocerciasis produces promising
results, then
• moxidectin should be evaluated for effectiveness against
LF parasites as soon as possible.
2.2.3 Research Needs: Clinical Drug Trials
Standardization of clinical trial techniques.
Clinical trials with existing and newer anti-filarial drugs are
needed to address many of the issues that have arisen during
implementation of the GPELF and to provide insights that
will strengthen the Program’s evidence base. Therefore,
• standard operating procedures need to be developed for
controlled clinical trials to assess the efficacy of anti-filarial
drugs and to define the methodologies used
a) to estimate mf density,
b) to calculate clearance of microfilaremia,
c) to define the time points at which determinations will be
made,
d) to provide evidence of the parasite adulticidal effects of
drug treatment (i.e., development of nodules post-
treatment, ultrasound follow-up of identified nests of
worms, and antigen detection assays at appropriate in-
tervals),
e) to document the side effects that may be less commonly
recognized (such as proteinurea or hematuria).
Optimizing clearance of mf.
While the currently recommended two-drug regimens ef-
fectively clear microfilaremia,16,20−22 if ways to improve them
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could be found, clear programmatic benefits might result.
Therefore, efforts to optimize the regimens need to be un-
dertaken in different regions and with different strains or
species of parasites
• by exploring alternative frequencies of treatment (e.g., six-
monthly),
• by defining the total number of treatments required in ar-
eas with different prevalences of infection,
• by evaluating the effects of higher dosages of ivermectin
(i.e., > 200 g/kg) and/or albendazole (i.e., > 400 mg) in the
two-drug co-administration regimens.
Recrudescence of microfilaremia post treatment is well rec-
ognized,23,24 but he factors that govern it are not well under-
stood. Therefore,
• controlled trials that follow microfilaremic individuals over
extended periods of time should be undertaken to identify
and define the factors that determine the reappearance of
microfilaremia in treated individuals.
Diethylcarbamazine-fortified salt.
The use of DEC-fortified salt is an alternative to repeated
single-dose regimens for interrupting transmission25 and
might be especially useful in those situations where reaching
the entire at risk population is particularly difficult (as in
urban populations). While DEC-fortified salt has docu-
mented effects on adult worms, decreased frequency of side
effects, and potential prophylactic benefits, it is unclear if the
presence of DEC, even at the low concentrations in fortified
salt, would make it unsafe for use in urban or other areas of
Africa where onchocerciasis might coexist. Also, current rec-
ommendations are for use of DEC-salt for a period of 1−2
years to achieve LF elimination, but studies to define the
optimal duration of treatment have not yet been carried out.
Therefore, additional studies are needed
• to evaluate the duration of use of DEC-salt yielding an
optimal anti-filarial outcome,
• to determine the lowest LF-effective dose of DEC-fortified
salt that could be safe for use in onchocerciasis-endemic
areas, either urban or where previous treatment with iver-
mectin had been adminstered,
• to explore the potential for enhanced efficacy of DEC-salt
when intermittent (e.g., once a year) albendazole is co-
administered.
Decreasing parasitologic response to therapy.
Success of the LF elimination program could be jeopar-
dized if a decrease in the efficacy of available drugs devel-
oped. Early identification of decreased susceptibility to cur-
rently available anti-filarial drugs is undoubtedly a most cost-
effective means for ensuring the continued, long-term success
of the LF elimination program. While analysis of changes in
the parasite genotype has the potential for providing both
baseline and situational information on the distribution and
frequency of resistant genotypes,10 a definition for resistant
phenotype has yet to be agreed, and the challenge is made
more difficult (particularly with respect to DEC) by the vari-
ability of responses in different individuals. For example,
many observations document the persistence of microfilare-
mia even after individuals or populations have received sev-
eral courses of DEC in single or multiple doses;23 and, just as
concerning is that only a proportion (∼70%) of adult W. ban-
crofti is usually killed by a single dose of DEC, with no ad-
ditional killing of the remaining worms even with additional
doses of the drug (documented by ultrasound).26 Therefore,
while to date there has been no documentation of the exis-
tence of resistance to DEC, ivermectin or albendazole in LF
parasites, there is now an urgent need
• to establish a working group to create a phenotypic defini-
tion of reduced responsiveness and drug resistance and to
identify the defining criteria that must be assessed,
• to estimate the frequency of occurrence of such reduced
responsiveness (e.g., by examining program data from
around the world) and to document the existence of the
problem in identified individuals who can be further stud-
ied,
• to develop a central repository of genetic material from mf
and adult worms in different endemic areas to facilitate
1) collection of base-line data on the occurrence of poten-
tial drug resistant genotypes,
2) implementation of an effective surveillance system for
drug resistance,
• to model drug resistance in LF so that the implications of
the possible emergence of resistance can be predicted and
deficiencies in relevant knowledge can be identified.
New drugs and drug combinations.
Endosymbiotic bacteria (Wolbachia spp.) within filarial
parasites influence the life cycle of the parasites to such a
degree that killing these bacteria produces adulticidal effects.
Recent trials in onchocerciasis and W. bancrofti infections
suggest that long-term (six-week) administration of tetracy-
cline may have profound anti-parasitic effects on adult filarial
parasites.27 Therefore, to find drug regimens that are more
practicable for public health programs,
• the adulticidal effects of various regimens of tetracyclines,
rifampicin, and combinations of antibiotics and conven-
tional anti-filarial drugs (such as DEC) should be evaluated
in controlled clinical trials.
Moxidectin is currently in early clinical stages of evaluation
for onchocerciasis. If this compound progresses satisfactorily
in clinical development,
• moxidectin should undergo clinical trials for evaluation of
adulticidal and/or microfilaricidal activity in LF.
While the safety and pharmacokinetics (PK) of the two-
drug co-administration regimens used for the LF MDA pro-
grams have been well established,12−14 increasingly the desir-
ability of linking LF programs with other public health initia-
tives also based on MDA is being appreciated. Similarly, the
increasingly widespread and long-term use of drugs to treat
populations with HIV/AIDS or TB means that many indi-
viduals could inadvertently receive their LF MDA drugs at
the same time as they are receiving other drugs as well. There
is a concern that excessive changes in the metabolism of al-
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bendazole and/or ivermectin might occur when these LF
drugs are administered to patients on anti-retroviral or anti-
TB therapy. For all these reasons,
• PK and safety studies should be conducted with the LF
MDA regimens and with those drugs used in other public
health initiatives that might be linked with the GPELF
(e.g., praziquantel [schistosomiasis], azithromycin [tra-
choma]),
• surveillance should be promoted for potential pharmacoki-
netic interactions between LF therapy and highly active
retroviral therapy for HIV/AIDS and combination therapy
for TB; if evidence for such potential interactions is found,
formal PK and safety studies should be undertaken.
Treating LF infection in individual patients.
Physicians and other health providers in endemic areas
must care for individual patients with individual treatment
regimens, but since these health providers in most countries
are only peripherally involved in the GPELF, many are un-
aware of the recent advances in the chemotherapy of LF (par-
ticularly the efficacy of single-dose treatment in curing infec-
tion). Current physician guidelines (including the major text-
books of medicine) do not refer to these recent advances;
indeed, even the WHO guidelines (last issued in 1992) do not
refer to the dramatic changes that have taken place in the
chemotherapy of LF. Consequently, tens of thousands of
medical students today are completely unaware of the
changed concepts of dosing and optimal regimens used to
treat LF.
The guidelines for program managers, focused on inter-
rupting LF transmission, are based on studies of the effects of
single-dose drugs and drug combinations on decreasing mi-
crofilaremia in individuals and populations. The principal
goal for treating individual patients, however, is to kill the
adult parasite. Guidelines for treating individual patients and
populations in endemic areas must be harmonized, and while
available information suggests that the same drug regimens
used in MDAs may also be optimal for the treatment of in-
dividual patients,
• clinical trials to define the optimal regimen of drugs and
drug combinations for treating individuals with LF are ur-
gently needed,
• in addition to defining the most effective drugs, clinical
trials must also resolve questions about
1) the optimal frequency, duration, and end point of treat-
ment,
2) the best tools for monitoring successful therapy.
Preventing LF infection (chemoprophylaxis).
The current global strategy based on annual single doses of
combinations of anti-filarial drugs aims to clear mf from in-
fected individuals. Healthy individuals in these areas may see
little value in consuming the drugs in the absence of any direct
personal benefits or long-term protection against the infec-
tion. Identification of agents or regimens that would afford
protective benefits to exposed individuals would likely en-
hance the interest of people in participating and, thus, the
success and sustainability of programs. Earlier studies in ani-
mal models and epidemiologic observations in human popu-
lations suggest that DEC (as individual doses or in fortified
table salt) may be prophylactic in LF. Therefore, it would be
valuable
• to develop a trial design that can identify prophylactic
properties of LF drugs in human populations,
• to assess the prophylactic effects of DEC, ivermectin, al-
bendazole and other newer drugs (such as moxidectin) in
human populations (as well as in animal models).
Minimizing treatment reactions.
A major programmatic challenge in LF control/elimination
programs based on drug administration has been the occur-
rence of post-treatment reactions in endemic populations, as
they sometimes threaten program implementation or expan-
sion. The advent of single dose chemotherapy has greatly
improved the compliance of populations, and while post-
treatment reactions are usually mild, self-limited and in most
situations require only symptomatic therapy, efforts to reduce
the occurrence of even these mild reactions could very much
improve compliance in control programs. Therefore, trials
should be undertaken
• to test novel approaches to minimizing the occurrence and
intensity of post-treatment reactions (e.g., by administering
the drugs in divided dose, with or without food, at different
times of the day, etc.),
• to compare the frequency and intensity of post-treatment
reactions following anti-Wolbachia treatment with those
following conventional anti-filarial treatment.
Treating LF in L. loa-endemic regions
Since the current recommendation for treating populations
in most LF-endemic countries of Africa calls for use of iver-
mectin (Mectizan) and albendazole, and since the risk-
benefit assessment of Mectizan administration in areas
where loaisis and LF coexist without onchocerciasis currently
is judged to weigh against MDA, large areas of central and
west Africa are excluded from the MDAs using the drug regi-
mens now available.28 Therefore, there is an urgent need
• to conduct clinical trials that examine the safety and effi-
cacy of a variety of anti-filarial regimens in areas were loia-
sis and LF coexist, with or without concurrent onchocer-
ciasis, including the recently initiated trials of albendazole
pre-treatment to reduce Loa mf densities prior to treat-
ment with ivermectin.
Lymphatic filariasis and traditional, indigenous medicine.
In many endemic countries numerous traditional and in-
digenous therapies are currently available and used for the
treatment of LF. In almost all instances these drugs and in-
terventions have not been evaluated in controlled clinical tri-
als. Therefore,
• efforts must be made to evaluate the efficacy and safety of
these traditional and indigenous therapies; if any is found
helpful, their incorporation into the GPELF should be en-
couraged.
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